Durability and outcome of initial antiretroviral treatments received during 2000--2005 by patients in the Swiss HIV Cohort Study.
about
Prevalence of transmitted drug resistance and impact of transmitted resistance on treatment success in the German HIV-1 Seroconverter CohortIncidence and predictors of first line antiretroviral regimen modification in western KenyaA randomized comparative trial of continued abacavir/lamivudine plus efavirenz or replacement with efavirenz/emtricitabine/tenofovir DF in hypercholesterolemic HIV-1 infected individualsReasons and Risk Factors for the Initial Regimen Modification in Chinese Treatment-Naïve Patients with HIV Infection: A Retrospective Cohort AnalysisFocus Group Evaluation of the LIVE Network-An Audio Music Program to Promote ART Adherence Self-Management.Gastrointestinal tolerability and quality of life in antiretroviral-naive HIV-1-infected patients: data from the CASTLE study.Rates and reasons for early change of first HAART in HIV-1-infected patients in 7 sites throughout the Caribbean and Latin America.Cumulative viral load and virologic decay patterns after antiretroviral therapy in HIV-infected subjects influence CD4 recovery and AIDSCost-effectiveness of HIV screening in STD clinics, emergency departments, and inpatient units: a model-based analysisOutcomes of highly active antiretroviral therapy in the context of universal access to healthcare: the U.S. Military HIV Natural History StudyChanging patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study.Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe.Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study.Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study.The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection.Safety and immunological responses to human mesenchymal stem cell therapy in difficult-to-treat HIV-1-infected patients.Japanese external quality assessment program to standardize HIV-1 drug-resistance testing (JEQS2010 program) using in vitro transcribed RNA as reference material.Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs.Elevated CD8 counts during HAART are associated with HIV virologic treatment failure.Clinical management of HIV drug resistance.Relationships between Serum Levels of Atazanavir and Renal Toxicity or Lithiasis.CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHEREA retrospective study of HIV antiretroviral treatment persistence in a commercially insured population in the United States.Temporal trends in the discontinuation of first-line antiretroviral therapyModifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients.Factors associated with the first antiretroviral therapy modification in older HIV-1 positive patients.Abacavir/lamivudine versus tenofovir/emtricitabine in virologically suppressed patients switching from ritonavir-boosted protease inhibitors to raltegravir.Discontinuation of Initial Antiretroviral Therapy in Clinical Practice: Moving Toward Individualized TherapyEffect of persistency of first-line HIV antiretroviral therapy on clinical outcomesToxicity-related antiretroviral drug treatment modifications in individuals starting therapy: a cohort analysis of time patterns, sex, and other risk factors.Long-term efficacy and safety of atazanavir/ritonavir treatment in a real-life cohort of treatment-experienced patients with HIV type 1 infectionDiscontinuation of antiretroviral therapy among adults receiving HIV care in the United States.Impact of previous virological treatment failures and adherence on the outcome of antiretroviral therapy in 2007.The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naive patients.Incidences and risk factors of first-line HAART discontinuation: a limitation to the success of the "seek, test, treat, and retain" strategy?Effect of gender and calendar year on time to and duration of virologic suppression among antiretroviral-naïve HIV-infected individuals initiating combination antiretroviral therapy.Effect of therapy switch on time to second-line antiretroviral treatment failure in HIV-infected patients.The influence of patient beliefs and treatment satisfaction on the discontinuation of current first-line antiretroviral regimens.Durability of antiretroviral therapy regimens and determinants for change in HIV-1-infected patients in the TREAT Asia HIV Observational Database (TAHOD-LITE).Durability of the first antiretroviral treatment regimen and reasons for change in patients with HIV infection.
P2860
Q28475698-84530C3B-3955-4BF0-91FE-B2272AF291BFQ28541822-38DFE9B2-5A82-4410-9DCC-3FC538B6ED6AQ28543212-40BAEA31-7B1A-462E-87BA-9B22712678B3Q28546795-54781521-4E68-4CE4-8658-52B8314F46A2Q30353427-AF1EFE3F-9608-4EC0-8075-690E76B3630AQ33578024-03B295B6-39CC-4928-99D3-4981F5F5DF7CQ33598309-5268F107-ABC8-482E-9F30-AECC347EB1EFQ33916321-0AB35EF0-0554-4C5B-BA0C-CF668A5DAB9CQ33916355-B141DCE8-5D2C-4E99-A264-9245F6EEDFF6Q33951598-17DE0EC2-ABF4-40D2-A579-74FE597F0419Q34059657-29A7AA93-586E-4FC4-836B-C801F85229E8Q34469240-D86DB741-AEB2-4164-9EE9-D22BE86F0C6EQ34474961-1581DDD1-26BE-4C3C-AA16-91B5E9B79487Q34763589-AE996019-6FF8-4448-9275-2F3CE51BC1B4Q35019915-12E8B744-C95A-48AB-94F3-D37F415E5AE5Q35087069-8E01BE88-1D8C-426F-8629-1E9FBB15E995Q35141797-F0393192-FEC8-4127-99CA-97DACB464085Q35147189-A6747BEB-498C-4A02-B485-C84822CB83B3Q35213754-FEB0F8BC-5CB1-4BAA-863F-A1760DE231C1Q35261045-A19D0643-F752-40C9-B5F0-0C53B9318B39Q35630635-6B1AC17A-4D3A-4488-9D1B-767AD05D4744Q35842386-DF5E19A1-B919-4478-8DBB-E1FB7724FD5DQ35872422-FEA2316D-3728-46A2-858D-DB7FE8AEB83DQ36093602-2D05CC6E-A77C-432E-AA8A-0AE1987B0E84Q36426953-949B004D-1A9A-4382-BD6F-A7806DA7B8AFQ36439314-1C5580CE-09EE-48BA-9BAF-FEB7C59ACE9CQ36553976-27024655-05DC-4107-8BC4-7420B05F46EAQ36628396-B1D14ED6-40A6-48A3-8B31-348054142760Q36715732-DEA99315-4A3D-40DD-8E75-0A886CDB97A9Q36954711-2BCB9040-E566-402C-A550-7F6CB550EABEQ36974067-2C45C0D9-7C22-400B-9267-70FDD2CDB2B6Q37388428-7764A19B-0C07-4B8D-83E1-C2ACD6C1FF18Q37463958-C4339459-67AE-4A82-8C64-1C1610844FC1Q37593100-A84C9D89-F34C-4C1D-9757-FF0E1AB6CE90Q38422291-F12F04C2-8BD9-47A7-A097-CD411F45027FQ38440869-5BA0D99A-7B74-4E65-87FB-17626FA20BBAQ38669988-5ED72C43-98CF-4C5C-865A-AFB8C86CFAA8Q40763424-AA129997-E6B6-42D7-AEEE-2B6C087279ACQ41995721-6D5CCB50-B9E8-4166-AD59-9FE042947C88Q42228869-EDE70FB2-0EF7-464B-9547-E1EAB7601AF0
P2860
Durability and outcome of initial antiretroviral treatments received during 2000--2005 by patients in the Swiss HIV Cohort Study.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Durability and outcome of init ...... in the Swiss HIV Cohort Study.
@en
Durability and outcome of init ...... in the Swiss HIV Cohort Study.
@nl
type
label
Durability and outcome of init ...... in the Swiss HIV Cohort Study.
@en
Durability and outcome of init ...... in the Swiss HIV Cohort Study.
@nl
prefLabel
Durability and outcome of init ...... in the Swiss HIV Cohort Study.
@en
Durability and outcome of init ...... in the Swiss HIV Cohort Study.
@nl
P2093
P50
P356
P1476
Durability and outcome of init ...... in the Swiss HIV Cohort Study.
@en
P2093
Bruno Ledergerber
Pietro Vernazza
Rainer Weber
Thi Tuyet Nhung Vo
P304
P356
10.1086/588141
P407
P50
P577
2008-06-01T00:00:00Z